まとめ
米国で新たに合成された薬は25 (2001年-2002年) から37 (2003年-2004年) に増加し,治療の進歩を示した. いくつかの重要な薬が処方箋を支配し,市場での存在と一致しました.
科学分野:
- 薬理学 薬理学とは
- ドラッグ開発 ドラッグ開発
- 治療薬として用いられる.
背景:
- 新薬の導入は,医薬品のイノベーションの重要な指標である.
- 医薬品市場のダイナミクスを理解することは,医療提供者や政策立案者にとって極めて重要です.
研究 の 目的:
- 1973年から1974年にかけて米国で導入された新合成薬の数と治療的分類をレビューする.
- 処方箋のパターンと特定の医薬品の市場シェアを分析する.
主な方法:
- 米国における新合成薬の導入に関する遡及的レビュー.
- 処方箋データを分析し,薬剤を活性成分と治療クラスによって分類する.
主要な成果:
- 薬物導入は1973年から1974年にかけて37件に上昇し,1971年から1972年にかけて25件から増加した.
- 新しく合成された薬は,9つの主要な治療的分類に分類された.
- 1974年,処方箋の68%は,単一成分126種,多成分76種を含む200種類の医薬品で満たされていました.
- 処方箋の量は,各治療クラス内の薬物製品の数と相関する.
結論:
- 1973年から1974年までの期間は,新薬導入の有望な増加を示しました.
- 新しい薬は,医師にとって重要な治療的進歩と選択肢を提供します.
- 処方薬の市場を支配する薬剤の数は集中しており,その治療的重要性とアクセシビリティを反映しています.
関連する概念動画
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).